Member Contact: James Campbell
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
Based in Melbourne, Australia, Patrys (ASX: PAB) is a drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. Patrys has recently in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development.
For further information on Patrys, visit www.patrys.com